Biomea Fusion, Inc. (Nasdaq: BMEA), a preclinical-stage biopharmaceutical company focused on the discovery, development and commercialization of irreversible small molecules to treat patients with genetically defined cancers, has announced the closing of its initial public offering of 9 million shares of its common stock at a public offering price of US$17 per share. Biomea’s common stock began trading on The Nasdaq Global Select Market on April 16, 2021 under the ticker symbol “BMEA.” The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Biomea, were US$153 million. In addition, Biomea has granted the underwriters a 30-day option to purchase up to an additional 1,350,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions and offering expenses.
Latham & Watkins LLP represented Biomea Fusion, Inc. in the transaction with a corporate deal team led by Bay Area partners Miles Jennings and Brian Cuneo, with associates Valerie Lau, Casey Tong, and Adam Zuckerman. Advice was also provided on intellectual property matters by Bay Area partner Judith Hasko, with associate Jekkie Kim; on benefits and compensation matters by Bay Area partner Ashley Wagner; on tax matters by Bay Area partner Katharine Moir, with associate Robbie Hemstreet; and on regulatory matters by Washington, D.C. partner Elizabeth Richards, with Bay Area counsel Betty Pang and Washington, D.C. associate Chad Jennings.
The firm also previously advised Biomea in its Series A Financing in January 2021.